DK3313884T3 - Anti-cd123-antistoffer og konjugater og derivater deraf - Google Patents

Anti-cd123-antistoffer og konjugater og derivater deraf Download PDF

Info

Publication number
DK3313884T3
DK3313884T3 DK16736718.4T DK16736718T DK3313884T3 DK 3313884 T3 DK3313884 T3 DK 3313884T3 DK 16736718 T DK16736718 T DK 16736718T DK 3313884 T3 DK3313884 T3 DK 3313884T3
Authority
DK
Denmark
Prior art keywords
conjugates
antibodies
derivatives
Prior art date
Application number
DK16736718.4T
Other languages
English (en)
Inventor
Yelena Kovtun
Daniel Tavares
Lingyun Rui
Thomas Chittenden
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Application granted granted Critical
Publication of DK3313884T3 publication Critical patent/DK3313884T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK16736718.4T 2015-06-29 2016-06-28 Anti-cd123-antistoffer og konjugater og derivater deraf DK3313884T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562186161P 2015-06-29 2015-06-29
US201662338203P 2016-05-18 2016-05-18
US201662346730P 2016-06-07 2016-06-07
PCT/US2016/039797 WO2017004026A1 (en) 2015-06-29 2016-06-28 Anti-cd 123 antibodies and conjugates and derivatives thereof

Publications (1)

Publication Number Publication Date
DK3313884T3 true DK3313884T3 (da) 2021-02-22

Family

ID=56373176

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16736718.4T DK3313884T3 (da) 2015-06-29 2016-06-28 Anti-cd123-antistoffer og konjugater og derivater deraf

Country Status (27)

Country Link
US (6) US10077313B2 (da)
EP (2) EP3313884B9 (da)
JP (2) JP7203497B2 (da)
KR (1) KR20180021177A (da)
CN (3) CN114672490A (da)
AR (1) AR105194A1 (da)
AU (2) AU2016285552B2 (da)
BR (1) BR112017027254A2 (da)
CA (1) CA2989321A1 (da)
CY (1) CY1123884T1 (da)
DK (1) DK3313884T3 (da)
ES (1) ES2887273T3 (da)
HK (1) HK1252976A1 (da)
HR (1) HRP20210263T1 (da)
HU (1) HUE053619T2 (da)
IL (2) IL256271B (da)
LT (1) LT3313884T (da)
MD (1) MD3313884T2 (da)
PL (1) PL3313884T3 (da)
PT (1) PT3313884T (da)
RS (1) RS61452B9 (da)
RU (1) RU2739612C2 (da)
SG (1) SG10202005144TA (da)
SI (1) SI3313884T1 (da)
TW (2) TW202134284A (da)
WO (1) WO2017004026A1 (da)
ZA (1) ZA202007918B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053619T2 (hu) 2015-06-29 2021-07-28 Immunogen Inc Anti-CD123 antitestek és konjugátumok és ezek származékai
LT3313845T (lt) 2015-06-29 2020-12-10 Immunogen, Inc. Cisteino inžinerijos antikūnų konjugatai
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
TWI755450B (zh) 2016-11-23 2022-02-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
TW201825515A (zh) * 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
AU2018213202B2 (en) * 2017-01-25 2022-03-24 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
JP7106560B2 (ja) 2017-02-28 2022-07-26 イミュノジェン・インコーポレーテッド 自己犠牲型ペプチドリンカーを有するメイタンシノイド誘導体及びそのコンジュゲート
AU2018335780A1 (en) * 2017-09-22 2020-03-26 Immunogen, Inc. Methods of preventing methionine oxidation in immunoconjugates
CN111163804A (zh) * 2017-09-22 2020-05-15 伊缪诺金公司 使用阳离子交换色谱法分离三轻链抗体
CN111164208B (zh) 2017-09-29 2023-08-04 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物
CA3205442A1 (en) * 2017-10-27 2019-05-02 Pfizer, Inc. Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
AU2019206587A1 (en) 2018-01-12 2020-08-06 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
CN116425874A (zh) * 2018-06-15 2023-07-14 康源博创生物科技(北京)有限公司 抗cd123抗体及其制备方法和应用
US20200157228A1 (en) * 2018-10-30 2020-05-21 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates
WO2020092344A1 (en) * 2018-10-31 2020-05-07 Health Research, Inc. Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor
AU2019379104A1 (en) 2018-11-12 2021-06-03 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
AU2019381628A1 (en) * 2018-11-12 2021-05-27 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
SG11202109569RA (en) * 2019-03-21 2021-10-28 Immunogen Inc Methods of preparing cell-binding agent-drug conjugates
CN113661172A (zh) 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
SG11202110702WA (en) * 2019-04-29 2021-11-29 Immunogen Inc Therapeutic combinations comprising anti-cd123 immunoconjugates
CN112646033B (zh) * 2020-12-16 2022-04-12 北京艺妙神州医药科技有限公司 靶向cd123的嵌合抗原受体及其用途
TW202330608A (zh) 2021-09-30 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 吡咯并苯并二氮雜卓類衍生物及其偶聯物、其製備方法及其應用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0229046B1 (fr) 1985-03-30 1994-05-04 BALLIVET, Marc Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
MXPA05004712A (es) 2002-11-07 2005-11-23 Immunogen Inc Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos.
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
WO2006024497A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
DK2913343T3 (da) * 2005-12-20 2018-11-26 Sbi Biotech Co Ltd Anti-ILT7-antistof
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
EP2287174B8 (en) 2008-01-18 2016-12-07 Bio-Rad Laboratories, Inc. Enhanced purification of antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
WO2010126066A1 (ja) * 2009-04-27 2010-11-04 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗IL-3Rα抗体
KR20130032866A (ko) * 2010-02-18 2013-04-02 더 유니버시티 오브 멜버른 만성 염증 상태의 치료
TW202348631A (zh) 2010-02-24 2023-12-16 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
MX346635B (es) * 2011-02-15 2017-03-27 Immunogen Inc Derivados citotoxicos de la benzodiazepina.
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
US20160031996A1 (en) 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
AU2014326674B2 (en) * 2013-09-26 2020-03-12 Ablynx Nv Bispecific nanobodies
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CA2947602A1 (en) * 2014-05-20 2015-11-26 Immunogen, Inc. Methods for characterizing and treating acute myeloid leukemia
US10988531B2 (en) * 2014-09-03 2021-04-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
ES2815353T3 (es) * 2014-09-03 2021-03-29 Immunogen Inc Derivados de benzodiazepina citotóxicos
EA037647B1 (ru) * 2014-09-05 2021-04-27 Янссен Фармацевтика Нв Агенты, связывающиеся с cd123, и виды их применения
LT3313845T (lt) 2015-06-29 2020-12-10 Immunogen, Inc. Cisteino inžinerijos antikūnų konjugatai
HUE053619T2 (hu) 2015-06-29 2021-07-28 Immunogen Inc Anti-CD123 antitestek és konjugátumok és ezek származékai
JP2019501139A (ja) * 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
TWI755450B (zh) * 2016-11-23 2022-02-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
CN111163804A (zh) * 2017-09-22 2020-05-15 伊缪诺金公司 使用阳离子交换色谱法分离三轻链抗体
AU2018335780A1 (en) * 2017-09-22 2020-03-26 Immunogen, Inc. Methods of preventing methionine oxidation in immunoconjugates
AU2019206587A1 (en) 2018-01-12 2020-08-06 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation

Also Published As

Publication number Publication date
PT3313884T (pt) 2021-02-25
AU2022291603A1 (en) 2023-02-02
AU2016285552A1 (en) 2018-01-18
RS61452B1 (sr) 2021-03-31
KR20180021177A (ko) 2018-02-28
SI3313884T1 (sl) 2021-04-30
SG10202005144TA (en) 2020-07-29
EP3842459A1 (en) 2021-06-30
US11332535B2 (en) 2022-05-17
PL3313884T3 (pl) 2021-05-31
TW201700498A (zh) 2017-01-01
EP3313884B1 (en) 2020-11-18
TW202134284A (zh) 2021-09-16
RU2017146345A3 (da) 2019-11-27
US11897961B2 (en) 2024-02-13
RU2017146345A (ru) 2019-07-29
HRP20210263T1 (hr) 2021-04-02
CY1123884T1 (el) 2022-05-27
CA2989321A1 (en) 2017-01-05
IL256271A (en) 2018-02-28
TWI727958B (zh) 2021-05-21
IL256271B (en) 2022-01-01
HUE053619T2 (hu) 2021-07-28
JP7203497B2 (ja) 2023-01-13
LT3313884T (lt) 2021-03-10
MD3313884T2 (ro) 2021-04-30
US20200239580A1 (en) 2020-07-30
CN107889493B (zh) 2022-02-01
US10077313B2 (en) 2018-09-18
US10875925B2 (en) 2020-12-29
US20210147560A1 (en) 2021-05-20
CN107889493A (zh) 2018-04-06
AR105194A1 (es) 2017-09-13
ZA202007918B (en) 2022-08-31
US20180079819A1 (en) 2018-03-22
RS61452B9 (sr) 2021-12-31
JP2023036869A (ja) 2023-03-14
US20170029514A1 (en) 2017-02-02
CN114672490A (zh) 2022-06-28
RU2739612C2 (ru) 2020-12-28
WO2017004026A1 (en) 2017-01-05
WO2017004026A8 (en) 2017-03-02
US10442865B2 (en) 2019-10-15
US20220372152A1 (en) 2022-11-24
BR112017027254A2 (pt) 2019-05-14
EP3313884A1 (en) 2018-05-02
CN114671951A (zh) 2022-06-28
US10919969B2 (en) 2021-02-16
EP3313884B9 (en) 2021-05-19
JP2018524349A (ja) 2018-08-30
HK1252976A1 (zh) 2019-06-06
US20180355047A1 (en) 2018-12-13
AU2016285552B2 (en) 2022-10-13
ES2887273T3 (es) 2021-12-22
IL288391A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
IL288391A (en) Anti-cd123 antibodies and conjugates and their history
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK3307274T3 (da) Anti-cd123-antistoffer og konjugater deraf
DK3515487T3 (da) Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3592393T3 (da) Frigørbare konjugater
IL290457A (en) Antibodies and their conjugates
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3579883T3 (da) Pyrrolobenzodiazepin-antistofkonjugater
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3191135T3 (da) Anti-HER2-antistoffer og immunokonjugater
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
BR112016021717A2 (pt) anticorpos anti-egfr e conjugados anticorpo-fármaco
DK3102244T3 (da) Antistoflægemiddelkonjugater og immuntoksiner
DK3270965T3 (da) Cd48-antistoffer og konjugater deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3004162T3 (da) Anti-væg-teichoin-antistoffer og konjugater
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil